Certara (NASDAQ:CERT) Releases FY 2026 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.310-0.340 for the period, compared to the consensus EPS estimate of 0.310. The company issued revenue guidance of $427.2 million-$431.4 million, compared to the consensus revenue estimate of $380.9 million.

Certara Stock Performance

CERT stock opened at $12.18 on Friday. Certara has a twelve month low of $4.45 and a twelve month high of $12.25. The company has a quick ratio of 2.55, a current ratio of 2.55 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.86 billion, a P/E ratio of -27.07 and a beta of 1.30. The business’s fifty day moving average is $9.26 and its 200-day moving average is $7.33.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09. The business had revenue of $94.90 million during the quarter, compared to analysts’ expectations of $92.01 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%. The firm’s quarterly revenue was down 9.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. Equities research analysts forecast that Certara will post 0.21 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on CERT shares. Barclays boosted their target price on Certara from $7.50 to $9.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. KeyCorp upped their price target on Certara from $9.00 to $12.00 and gave the company an “overweight” rating in a research note on Friday, October 16th. TD Cowen increased their price target on shares of Certara from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Weiss Ratings lowered shares of Certara from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, October 8th. Finally, UBS Group reissued a “neutral” rating and set a $13.00 price objective on shares of Certara in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $9.45.

Key Headlines Impacting Certara

Here are the key news stories impacting Certara this week:

• Positive Sentiment: Certara raised its 2026 revenue guidance to $427.2 million–$431.4 million, well above the roughly $380.9 million analyst consensus. Its EPS outlook of $0.31–$0.34 also reached or exceeded expectations, signaling improved revenue prospects. Why Did Certara Shares Climb?
• Positive Sentiment: Q3 revenue of $94.9 million exceeded estimates of $92.01 million. Coverage highlighted double-digit software revenue growth—the first time in two years—and expanding margins, supporting optimism about the business mix and operating performance. Q3 Earnings Call Highlights
• Neutral Sentiment: Certara reported Q3 EPS of $0.09, meeting some consensus estimates and topping the Zacks estimate of $0.08. The company also appointed Grant Peterson as chief product officer. Third-Quarter Results
• Negative Sentiment: Despite beating the revenue estimate, total Q3 revenue declined 9.3% year over year, and EPS was below the $0.14 reported a year earlier. That comparison tempers the positive outlook and software-growth news. Q3 Earnings and Revenue

Certara Company Profile

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.